Eloralintide: Peptide Profile, CAS & Properties
CAS 2883634-40-8 · 4526.10 g/mol
Eloralintide (CAS 2883634-40-8; also LY3841136) is a 37-amino-acid selective amylin receptor agonist of the amylin and co-agonist peptide class, molecular formula C201H319N49O65S2 (~4526.10 g/mol). It is investigational and in clinical development for obesity, not yet approved by major regulators. This page provides reference information on Eloralintide.
- CAS Number
- 2883634-40-8
- Molecular Formula
- C201H319N49O65S2
- Molecular Weight
- 4526.10 g/mol
- Drug Class
- amylin receptor agonist
What is Eloralintide?
Eloralintide is a long-acting, selective amylin receptor agonist (also referenced in the literature as LY3841136) developed as a once-weekly subcutaneous candidate for obesity and weight management. It is a 37-amino-acid, C-terminally amidated peptide engineered for receptor selectivity and metabolic stability: two cysteine residues are joined through a methylene-thioacetal bridge, non-coded residues are incorporated within the chain, and a lysine is acylated with a γGlu-γGlu spacer linked to a C20 fatty di-acid for albumin binding and extended half-life. Mechanistically it acts as an agonist at the amylin receptor family, preferentially activating the amylin-1 receptor (AMY1R) over the calcitonin receptor, an action associated with satiety signalling.
As an active pharmaceutical ingredient (API), eloralintide (CAS 2883634-40-8, molecular formula C201H319N49O65S2, ~4526.10 g/mol) is typically handled as a lyophilised powder for formulation work. It is investigational — in clinical development and not yet approved by the US FDA, EMA or other major regulators for therapeutic use.
How Eloralintide Is Produced & Characterised
Eloralintide is a synthetically demanding peptide: the 37-mer length, the internal methylene-thioacetal cyclisation, the non-coded residues and the C20 di-acid side-chain conjugation all create opportunities for deletion sequences, diastereomers, incomplete cyclisation and incomplete acylation. Across the industry, peptides of this class are generally assembled by optimised Fmoc solid-phase peptide synthesis (SPPS) with controlled cyclisation and side-chain conjugation, followed by purification on preparative dynamic axial compression (DAC) HPLC columns that resolve the target sequence from closely related impurities.
For reproducible material, processes are typically optimised for batch-to-batch consistency from milligram optimisation runs through gram and kilogram quantities, with the final product lyophilised to a stable, uniform powder. Process development, technology transfer and scale-up are the usual stages by which such a candidate progresses from early research through clinical supply to larger volumes.
Typical Quality Specifications & Impurity Control
For a peptide API of this complexity, batches are generally characterised against a defined specification supported by a Certificate of Analysis (COA). Purity is typically determined by UPLC/HPLC, while sequence identity and minor structural variants are confirmed by LC-MS impurity profiling. Reference-grade material is commonly targeted at ≥99.0% purity, with individual impurities controlled below 0.10%, supported by ICH Q1A(R2) long-term and accelerated stability data.
Traceability from raw materials and resins through to final batch-release records, analytical methods validated to ICH Q2(R1), and characterisation of water content, counter-ion content, residual solvents and peptide content are the typical attributes that make such an API suitable for regulated formulation development and reference-standard use.
Regulatory & Documentation Context
Because eloralintide is investigational and not yet approved, programmes that use it generally rely on CMC documentation to support regulatory filings for investigational medicines. For a candidate at this stage that typically includes CTD Module 3 CMC sections (for IND/IMPD referencing), analytical validation packages aligned to ICH Q2(R1), and stability data; a US-DMF dossier may follow as a programme advances.
Quality systems for investigational APIs are generally framed around inspection readiness aligned to FDA, EMA and PMDA expectations. As eloralintide is investigational and not yet approved for therapeutic use, no efficacy, therapeutic-benefit or prescribing claims can be made about it. This page is provided for general reference and educational purposes only and is not medical, prescribing or commercial advice.
Eloralintide API — Specifications
| CAS Number | 2883634-40-8 |
|---|---|
| Molecular Formula | C201H319N49O65S2 |
| Molecular Weight | 4526.10 g/mol |
| Sequence | 37 amino acids, amidated, methylene-thioacetal bridge, C20 di-acid side chain |
| Drug Class | Selective amylin receptor agonist |
| Approval Status | Investigational — in clinical development, not yet approved |
| Appearance | White to off-white lyophilised powder |
| Typical Purity (HPLC) | ≥ 99.0% (single impurity < 0.10%) |
| Synthesis Route | Fmoc SPPS + DAC prep-HPLC purification |
| Regulatory Status | Investigational; not yet approved by FDA, EMA or other major regulators |
| Storage | Store at -20°C, protected from light & moisture |
| Form | Lyophilised powder (active pharmaceutical ingredient) |
Reference data only — WinHyCare neither supplies nor manufactures this compound; see our Semaglutide API for the product we supply. Regulatory status: Investigational; in clinical development for obesity and weight management and not yet approved by the US FDA, EMA or other major regulators.
Eloralintide API — Frequently Asked Questions
What is Eloralintide?
Eloralintide (also referenced as LY3841136) is an investigational, long-acting selective amylin receptor agonist. It is a 37-amino-acid, C-terminally amidated peptide with an internal methylene-thioacetal bridge and a C20 di-acid acylated side chain, developed as a once-weekly subcutaneous candidate for obesity and weight management.
What is the CAS number and molecular weight of Eloralintide?
Eloralintide's CAS number is 2883634-40-8, its molecular formula is C201H319N49O65S2, and its molecular weight is approximately 4526.10 g/mol. It is a 37-amino-acid selective amylin receptor agonist with an internal methylene-thioacetal bridge and a C20 di-acid acylated side chain.
Is Eloralintide approved by the FDA or EMA?
No. Eloralintide is investigational and in clinical development for obesity and weight management. It is not yet approved by the US FDA, EMA or other major regulators for therapeutic use, and no efficacy or therapeutic-benefit claims can be made about it.
What class of peptide is Eloralintide?
Eloralintide belongs to the amylin and co-agonist peptide class. It is a selective amylin receptor agonist that preferentially activates the amylin-1 receptor (AMY1R) over the calcitonin receptor, an action associated with satiety signalling.
What is Eloralintide being studied for?
Eloralintide is being studied in clinical development as a once-weekly subcutaneous candidate for obesity and weight management. Its receptor selectivity and acylated, half-life-extended design are intended to support sustained amylin-receptor signalling associated with appetite regulation.
How is Eloralintide produced?
Peptides of this class are generally produced by optimised Fmoc solid-phase peptide synthesis (SPPS) with controlled cyclisation and lipid side-chain conjugation, followed by preparative dynamic axial compression (DAC) HPLC purification and lyophilisation to a stable powder. The 37-mer length and structural modifications make careful impurity control during synthesis particularly important.
Related Peptide APIs
Cagrilintide API
CAS 1415456-99-3
GLP-1 & Incretin Multi-AgonistsAmycretin API
CAS 3005889-81-3
GLP-1 & Incretin Multi-AgonistsSemaglutide API
CAS 910463-68-2
GLP-1 & Incretin Multi-AgonistsRetatrutide API
CAS 2381089-83-2
Technical Reference Page
WinHyCare neither supplies nor manufactures Eloralintide; this page is provided as a technical reference. The peptide API we supply is Semaglutide.